

KURZPROTOKOLL
IMMU-132-09

Öffentlicher Titel	Phase III Studie zu Sacituzumab Govitecan bei rezidiviertem/refraktärem HR+/HER2-metastasiertem Brustkrebs
Wissenschaftl. Titel	Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens
Kurztitel	IMMU-132-09
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, Pharma-Studie, zweiarmig
Studienphase	Phase III
Erkrankung	Geschlechtsorgane: Brustkrebs: Zweitlinie oder höher
Einschlusskriterien	- Female or male subjects aged ≥ 18 years at the time of signing the informed consent form - Documented evidence of hormone receptor-positive HER2-negative (HR+/HER2-) MBC confirmed - Refractory to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for MBC including: At least 1 prior anticancer hormonal treatment, At least 1 cyclin-dependent kinase inhibitor 4/6 in the metastatic setting - Eligible for one of the chemotherapy options listed in the TPC arm - Documented disease progression after the most recent therapy - Adequate bone marrow function (hemoglobin > 9 g/dL, ANC $> 1,500$ per mm³, platelets $> 100,000$ per mm³) - Adequate renal function: calculated creatinine clearance ≥ 30 mL/minute according to the Cockcroft and Gault formula - Adequate hepatic function (bilirubin ≤ 1.5 IULN, AST and ALT $\leq 2.5 \times$ IULN or $5.0 \times$ IULN) - Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta human chorionic gonadotropin [β-hCG])
Ausschlusskriterien	- Previous treatment with Topoisomerase 1 Inhibitors as a free form or as other formulations - History of significant cardiovascular disease or clinically significant ECG abnormality - Patients with Gilbert's disease - Active infection requiring intravenous antibiotic use - Patients with a history of an anaphylactic reaction to irinotecan - Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations - Locally advanced MBC (stage IIIC) in subjects who are candidates for curative intent therapy at the time of study enrollment
Alter	18 Jahre und älter
Molekularer Marker	HER2/neu neg. PR HER2/neu neg./ER pos. ER HER2/neu neg./PR pos.

KURZPROTOKOLL
IMMU-132-09

Prüfzentren	Centrum für Hämatologie und Onkologie Bethanien (Rekrutierung beendet) Im Prüfling 17-19 60389 Frankfurt am Main Prof. Dr. med Hans Tesch Tel: 069 451080 Fax: 069 458257 hans.tesch@telemed.de
Sponsor	Immunomedics
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT03901339 EudraCT 2018-004201-33